#USA #Cambridge #Marengo Therapeutics #Nectin-4 #TriSTAR Platform

Marengo Therapeutics to Present Innovations in Cancer Therapy at SITC 2025

Marengo Therapeutics, a pioneering clinical-stage biotechnology company known for its innovative work in precision immunotherapy, is gearing up to showcase substantial advancements at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, scheduled for November 5-9 in National Harbor, Maryland. This year's presentation is particularly significant as it marks the first public disclosure of preclinical data on Marengo's lead program, TriSTAR0701, a dual-payload T cell engager specifically targeting Nectin-4, a clinically validated tumor antigen prevalent across various solid tumors.

About the TriSTAR Platform

The TriSTAR (Tri-specific T cell Engager) platform represents a groundbreaking approach in cancer treatment, focusing on harnessing the potential of T cells—crucial components of the immune system—in combating tumors. Nectin-4 is recognized for its overexpression in several cancers, including urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), and esophageal cancer. By specifically targeting this tumor antigen, the TriSTAR platform aims to unlock potent and durable antitumor activities that have the potential to improve patient outcomes significantly.

Dr. Zhen Su, CEO of Marengo Therapeutics, expressed enthusiasm about the developments, stating, “The TriSTAR platform represents the next frontier in precision T cell engagers designed to harness the diversity of the T cell repertoire and selectively redirect unique T cell subsets against compelling tumor targets. The unveiling of Nectin-4 as the inaugural target of our TriSTAR platform is a vital milestone as we expand our pipeline.”

Highlighted Presentations at SITC 2025

During the SITC Annual Meeting, Marengo will present several preclinical studies in collaboration with the National Cancer Institute (NCI), emphasizing the potential of rational combinations of Marengo's leading candidate, Invikafusp alfa. These presentations aim to explore its synergy with established treatment modalities, such as immune checkpoint inhibitors, chemotherapy, and targeted therapies.

Presentation Highlights

1. Title: TriSTAR0701, a first-in-class T cell receptor β chain-directed T cell engager
- Session Date: November 8
- Abstract Number: 914
- This presentation will focus on how TriSTAR0701 retargets specific T cell subsets to effectively engage Nectin-4 expressing tumors, aiming to enhance antitumor activity.

2. Title: Triple combination therapy in immune checkpoint blockade-refractory models
- Session Date: November 7
- This session will explore the efficacy of combining TriSTAR0701 with cisplatin and anti-PD-1 in murine models that do not respond to traditional checkpoint inhibitors.

3. Title: Novel anti-TCR Vβ targeted bispecific antibody
- Session Date: November 8
- This study will delve into the enhancement of immune responses in prostate cancer models using this innovative bispecific antibody in tandem with a PARP inhibitor.

4. Title: IL-2 fusion molecule promoting CD8+ T cell memory
- Session Date: November 7
- This presentation will focus on a unique IL-2 fusion molecule and its ability to support memory T cell formation in tumor environments, further optimized by HDAC inhibitors.

5. Title: Epigenetic modulation in combination with TCRβ-targeted IL-2
- Session Date: November 7
- This study will evaluate the synergistic effects of combining epigenetic drugs with IL-2 for MHC-I independent tumor control through CD8+ T cell activation.

Throughout these presentations, Marengo aims to validate the transformative potential of its innovative therapeutic regimens intended to enhance antitumor immune responses. This progression reflects the commitment of Marengo Therapeutics to develop novel immunotherapy approaches that are not only pioneering but also effective for a broad range of patients battling various cancers.

About Marengo Therapeutics and Its Vision

Marengo Therapeutics believes that a meticulous focus on the diverse T cell repertoire can yield significant advancements in cancer treatment. The company continues to advance its proprietary platforms, including the Selective T Cell Activation Repertoire (STAR), TriSTAR, and T cell Depletor (MSTAR), to precisely target and activate the right immune responses against cancer.

As the scientific and medical communities anticipate the insights from Marengo's presentations, it is evident that the merging of advanced therapeutic platforms and collaborative research efforts may carve a new path in oncology, potentially leading to more successful outcomes for patients across the spectrum of solid tumors.

For further updates and detailed insights, interested parties can visit Marengo's official website.